Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB307 Monotherapy and in Combination with Pembrolizumab in Advanced PSMA+ Solid Tumours
NCT04839991Phase 1Recruiting
- Sponsor
- Crescendo Biologics
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of 89Zr-CB307 in solid tumor and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Crescendo Biologics. Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at 20 months and Number of participants with treatment-related adverse events with CB307 in combination with pembrolizumab at 20 months. Started Jun 2021; status: recruiting.
02
Drugs
89Zr-CB307
03
Conditions
solid tumormetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04839991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839991.